References
- Khan FH, Pandian V, Ramraj SK, et al. RD3 loss dictates high-risk aggressive neuroblastoma and poor clinical outcomes. Oncotarget 2015;6:36522–36534.
- Cotterill SJ, Pearson AD, Pritchard J, et al. Clinical prognostic factors in 1277 patients with neuroblastoma: results of The European Neuroblastoma Study Group ‘Survey’ 1982–1992. Eur J Cancer 2000;36:901–908.
- Ambros PF, Ambros IM, Brodeur GM, et al. International consensus for neuroblastoma molecular diagnostics: report from the International Neuroblastoma Risk Group (INRG) Biology Committee. Br J Cancer 2009;100:1471–1482.
- Westermark UK, Wilhelm M, Frenzel A, et al. The MYCN oncogene and differentiation in neuroblastoma. Semin Cancer Biol 2011;21:256–266.
- Huang M, Weiss WA. Neuroblastoma and MYCN. Cold Spring Harb Perspect Med 2013;3:a014415.
- Janardhanan R, Banik NL, Ray SK. N-Myc down regulation induced differentiation, early cell cycle exit, and apoptosis in human malignant neuroblastoma cells having wild type or mutant p53. Biochem Pharmacol 2009;78:1105–1114.
- Light JE, Koyama H, Minturn JE, et al. Clinical significance of NTRK family gene expression in neuroblastomas. Pediatr Blood Cancer 2012;59:226–232.
- Schramm A, Schulte JH, Astrahantseff K, et al. Biological effects of TrkA and TrkB receptor signaling in neuroblastoma. Cancer Lett 2005;228:143–153.
- Park JR, Bagatell R, London WB, et al. Children's Oncology Group's 2013 blueprint for research: neuroblastoma. Pediatr Blood Cancer 2013;60:985–993.
- Navarro S, Amann G, Beiske K, et al. Prognostic value of international neuroblastoma pathology classification in localized resectable peripheral neuroblastic tumors: a histopathologic study of localized neuroblastoma European Study Group 94.01 Trial and Protocol. J Clin Oncol 2006;24:695–699.
- Aterman K, Schueller EF. Maturation of neuroblastoma to ganglioneuroma. Am J Dis Child 1970;120:217–222.
- Rozmus J, Langer M, Murphy JJ, et al. Multiple persistent ganglioneuromas likely arising from the spontaneous maturation of metastatic neuroblastoma. J Pediatr Hematol Oncol 2012;34:151–153.
- Salim A, Mullassery D, Pizer B, et al. Neuroblastoma: a 20-year experience in a UK regional centre. Pediatr Blood Cancer 2011;57:1254–1260.
- Strother DR, London WB, Schmidt ML, et al. Outcome after surgery alone or with restricted use of chemotherapy for patients with low-risk neuroblastoma: results of Children's Oncology Group study P9641. ClinOncol 2012;30:1842–1848.
- De Bernardi B, Mosseri V, Rubie H, et al. Treatment of localised resectable neuroblastoma results of the LNESG1 study by the SIOP Europe Neuroblastoma Group. Br J Cancer 2008;99:1027–1033.
- Shimada H, Nakagawa A, Peters J, et al. TrkA expression in peripheral neuroblastic tumors: prognostic significance and biological relevance. Cancer 2004;101(8):1873–1881.
- Ghali VS, Gold JE, Vincent RA, et al. Malignant peripheral nerve sheath tumor arising spontaneously from retroperitoneal ganglioneuroma: a case report, review of the literature, and immunohistochemical study. Hum Pathol 1992;23:72–75.
- Kattepura S, Alexander B, Kini U, et al. Sporadic synchronous ganglioneuromas in a child–case report and review. J Pediatr Surg 2010;45:822–825.